Letters Ebola virus vaccines

Ebola vaccines based on adenovirus vectors and risk of HIV

BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h1307 (Published 10 March 2015) Cite this as: BMJ 2015;350:h1307
  1. Eric J Kremer, INSERM director of research1,
  2. Philippe Van de Perre, professor2
  1. 1Institut de Génétique Moléculaire de Montpellier, Université Montpellier; INSERM U 1058, CHU 34293 Montpelier, France
  2. 2INSERM U 1058, Pathogenesis and Control of Chronic Infections, University of Montpellier, Montpellier, France
  1. eric.kremer{at}igmm.cnrs.fr

Under intense pressure to react, WHO is set to fast track phase II-III evaluation of candidate Ebola virus vaccines based on adenovirus vectors in west and central Africa.1

However, adenovirus vectors regularly show encouraging preclinical results but disappointing clinical efficacy. Despite the immunogenicity shown in phase II-III studies, two proof of concept HIV vaccine trials (STEP and Phambili) that used an adenovirus vector …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe